硫代海因类雄激素受体拮抗剂治疗去势抵抗性前列腺癌（CRPC）的构效关系。
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
机构信息
Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, USA.
出版信息
J Med Chem. 2010 Apr 8;53(7):2779-96. doi: 10.1021/jm901488g.
Abstract
A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate cancer.
摘要
进行了一系列硫代海因及其类似物 14 的构效关系研究，发现 92（MDV3100）可作为治疗激素难治性前列腺癌的临床候选药物。
相似文献
1
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
J Med Chem. 2010 Apr 8;53(7):2779-96. doi: 10.1021/jm901488g.
2
Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Prostate. 2011 Sep;71(12):1344-56. doi: 10.1002/pros.21351. Epub 2011 Feb 9.
3
Androgen receptor antagonists in castration-resistant prostate cancer.
Cancer J. 2013 Jan-Feb;19(1):43-9. doi: 10.1097/PPO.0b013e318282635a.
4
Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
Bioorg Med Chem. 2021 Feb 1;31:115953. doi: 10.1016/j.bmc.2020.115953. Epub 2020 Dec 16.
5
Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer.
Bioorg Med Chem. 2010 Dec 1;18(23):8150-7. doi: 10.1016/j.bmc.2010.10.023. Epub 2010 Oct 15.
6
Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Prostate. 2013 Nov;73(15):1699-709. doi: 10.1002/pros.22711. Epub 2013 Jul 19.
7
Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
Eur J Med Chem. 2018 Jan 1;143:1325-1344. doi: 10.1016/j.ejmech.2017.10.031. Epub 2017 Oct 14.
8
Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists.
Bioorg Med Chem. 2010 May 1;18(9):3159-68. doi: 10.1016/j.bmc.2010.03.036. Epub 2010 Mar 19.
9
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Clin Cancer Res. 2013 Oct 15;19(20):5613-25. doi: 10.1158/1078-0432.CCR-13-1151. Epub 2013 Aug 30.
10
Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
Eur J Med Chem. 2020 Apr 15;192:112196. doi: 10.1016/j.ejmech.2020.112196. Epub 2020 Mar 5.
引用本文的文献
1
Total Syntheses of Deuterated Drugs: A Comprehensive Review.
Top Curr Chem (Cham). 2025 Aug 21;383(3):31. doi: 10.1007/s41061-025-00515-x.
2
Recent Development in Hydantoins, Thiohydantoins, and Selenohydantoins as Anticancer Agents: Structure-activity Relationship and Design Strategies.
Mini Rev Med Chem. 2025;25(9):693-726. doi: 10.2174/0113895575329643241206101210.
3
Calcium Activation of the Androgen Receptor in Prostate Cells.
Int J Endocrinol. 2023 Dec 13;2023:9907948. doi: 10.1155/2023/9907948. eCollection 2023.
4
An Aminosteroid Derivative Shows Higher In Vitro and In Vivo Potencies than Gold Standard Drugs in Androgen-Dependent Prostate Cancer Models.
Cancers (Basel). 2023 Jun 2;15(11):3033. doi: 10.3390/cancers15113033.
5
DeepAR: a novel deep learning-based hybrid framework for the interpretable prediction of androgen receptor antagonists.
J Cheminform. 2023 May 6;15(1):50. doi: 10.1186/s13321-023-00721-z.
6
One-Pot High-throughput Synthesis of 3-Substituted 5-Arylidene-2-Thiohydantoin Amides and Acids.
Tetrahedron Lett. 2022 Aug 3;103. doi: 10.1016/j.tetlet.2022.153983. Epub 2022 Jun 30.
7
Synthesis and Biological Evaluation of Novel -Indolinones with Anticancer Activity.
Molecules. 2023 Jan 30;28(3):1325. doi: 10.3390/molecules28031325.
8
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
Cancer Res. 2023 Jan 18;83(2):219-238. doi: 10.1158/0008-5472.CAN-22-1533.
9
Synthesis of Hydantoin Androgen Receptor Antagonists and Study on Their Antagonistic Activity.
Molecules. 2022 Sep 10;27(18):5867. doi: 10.3390/molecules27185867.
10
Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.
J Med Chem. 2022 Aug 11;65(15):10441-10458. doi: 10.1021/acs.jmedchem.2c00453. Epub 2022 Jul 22.
本文引用的文献
1
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.
2
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats.
Endocrinology. 2007 Jan;148(1):4-12. doi: 10.1210/en.2006-0843. Epub 2006 Sep 28.
3
Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6201-6. doi: 10.1073/pnas.0500381102. Epub 2005 Apr 15.
4
Molecular determinants of resistance to antiandrogen therapy.
Nat Med. 2004 Jan;10(1):33-9. doi: 10.1038/nm972. Epub 2003 Dec 21.
5
Androgen receptor as a target in androgen-independent prostate cancer.
Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. doi: 10.1016/s0090-4295(02)01593-5.
6
Molecular biology of the androgen receptor.
J Clin Oncol. 2002 Jul 1;20(13):3001-15. doi: 10.1200/JCO.2002.10.018.
7
The development of androgen-independent prostate cancer.
Nat Rev Cancer. 2001 Oct;1(1):34-45. doi: 10.1038/35094009.
8
Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands.
J Med Chem. 2001 May 24;44(11):1729-40. doi: 10.1021/jm0005353.
9
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4904-9. doi: 10.1073/pnas.081565498.
10
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.
J Biol Chem. 2000 Aug 25;275(34):26164-71. doi: 10.1074/jbc.M004571200.
Zotero 插件